Pharmacies are being pushed to the breaking point by a mounting concessionary pricing crisis - how much more can they endure?
With the sector already awaiting clarity on a new contractual settlement, pharmacies are suffering financial pain with little to no clue when relief may come.
Put simply, pharmacists are being forced to fulfil scripts at a cost greater than they are reimbursed via the drug tariff. Supplying prescription drugs that they are effectively losing money on - that is clearly not a sustainable model for any business.
Concessionary pricing has always created challenges for contractors, but the scale and frequency of concessions today suggest the system is no longer fit for purpose.
The numbers alone tell an eye-watering story.
Industry reports showed 146 concessions across the market in January 2026. By March, that figure had climbed to a record 201, a rise of almost 38 percent in just two months.
With global supply pressures showing little sign of easing, there are increasing concerns that pharmacies could face even greater concessionary pricing pressure in the months ahead.
Behind every concession sits the same fundamental problem. Pharmacies are purchasing medicines above tariff and dispensing at a loss while waiting for the Department of Health to grant a concession, approving a temporary uplift to reimbursement pricing.
Losing battle
The issue is not simply that concessions exist. It is the speed, consistency and unpredictability of the process itself.
Contractors are often left carrying losses for extended periods without knowing whether a concession will be granted, when it will arrive, or how long pricing pressure will continue.
At a time when community pharmacy remains significantly underfunded, that uncertainty is becoming increasingly difficult to absorb.
For independent pharmacies in particular, the pressure can quickly become unsustainable.
Every contractor understands their obligation to patients, but there is an uncomfortable reality developing across the market where pharmacies are repeatedly expected to supply medicines below acquisition cost with no immediate certainty around recovery.
That creates impossible operational decisions.
It is no secret within the sector that some independents are now reluctantly directing patients elsewhere for certain lines because they simply cannot continue absorbing repeated losses.
Publicly, very few will admit to it, but privately everybody recognises the pressure that concessionary pricing is heaping on contractors.
The result is disruption for patients, fragmentation of care and additional strain on pharmacy teams already operating under enormous workload pressures.
For larger operators, the challenge remains significant even where scale and stockholding capacity may offer slightly more resilience.
The wider concern is what this says about the UK medicines market more broadly - and what that means for the future.
Unattractive pricing
Generic market pricing levels have been driven so low that the UK is becoming an increasingly unattractive market for manufacturers.
If suppliers can achieve significantly stronger returns elsewhere, it becomes harder to secure stable supply into the UK.
Global supply disruption, manufacturing issues, and rising shipping costs have all added further volatility into the medicines market in recent years.
The problem for contractors is that reimbursement mechanisms are often failing to keep pace with sudden acquisition cost increases, leaving pharmacies exposed financially while concessions slowly catch up.
Once availability tightens, the market reacts quickly. Prices spike, buying behaviour changes and shortages intensify.
We have already seen how rapidly this can happen. Aspirin became one of the clearest examples after manufacturing disruption caused prices to rise dramatically within a short period before gradually stabilising again.
The current concessionary pricing framework was not designed to operate at this level of sustained volatility.
What is increasingly frustrating for contractors is that pharmacies continue to act as the shock absorber for the entire system. The expectation remains that contractors will continue dispensing regardless of acquisition cost while reimbursement mechanisms slowly catch up behind the market.
That position is becoming harder to defend.
The rallying cry from contractors is simple. Pharmacies cannot continue being expected to dispense at a loss while waiting for concessions to catch up. The mechanism itself now needs urgent reform.
At the very least, the Department of Health needs to review the responsiveness of the concessions process and whether reimbursement is accurately reflecting real-time market conditions.
The current situation leaves too many pharmacies carrying too much financial risk for too long.
Community pharmacy continues to deliver more clinical services, relieve pressure across primary care and improve access for patients every single day. But none of that changes the fact that the sector cannot continue operating sustainably while regularly dispensing medicines at a loss.
Concessionary pricing was intended to protect pharmacies during periods of market instability. Increasingly, contractors would argue that the mechanism itself is now becoming part of the instability.
(Jeremy Meader is chief wholesale officer, Bestway Healthcare)
